Navigation Links
Pharmasset Reports Fiscal Second Quarter 2009 Financial Results
Date:5/11/2009

of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2008 and our Quarterly Report on Form 10-Q for the period ended March 31, 2009 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.


                                  PHARMASSET, INC.
            CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE NET LOSS
                                     (UNAUDITED)

                           Three Months Ended           Six Months Ended
                               March 31,                   March 31,
                               ---------                   ---------
                           2009          2008          2009          2008
                           ----          ----          ----          ----

    REVENUES            $1,902,679      $464,292    $2,366,970      $928,583
                        ----------      --------    ----------      --------

    COSTS AND EXPENSES:
      Research and
       development      13,694,247     8,990,469    27,717,177    19,540,840
      General and
       administrative    2,893,504     3,809,073     6,962,874     6,428,818
                         ---------     
'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th
3. Pharmasset Accesses up to $30 Million of Working Capital
4. Pharmasset to Present at Three Investor Conferences in November 2007
5. Pharmasset Appoints Michael Rogers as Chief Development Officer
6. Pharmasset Reports Fiscal Year End 2007 Financial Results
7. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
8. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
9. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
10. Pharmasset Appoints Herbert J. Conrad as a Director
11. Pharmasset Receives $10 Million of Working Capital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... According to a new market research report ... and Joint) Market (By Technology - Stem Cell ... Bone Graft Substitutes, Osteoarticular Diseases, Allogeneic Products, Autogenic ... Share, Growth, Trends and Forecast, 2013 - 2019" ... was valued at USD 2.6 billion in 2012 ...
(Date:7/28/2014)... CA and Annapolis Junction, MD (PRWEB) July 28, 2014 ... and research leader in personalized medicine, will be exhibiting ... services at this year’s International Spine Intervention Society’s ... take place July 30th-August 3rd, at the Hyatt Regency, ... designed to enhance the knowledge and clinical competence of ...
(Date:7/28/2014)... 28, 2014 Research and Markets ... Biology Market 2014-2018" report to their offering. ... term synthetic biology covers the designing and engineering of ... as the redesigning of natural biological systems that provide ... a form of extreme genetic engineering because it not ...
(Date:7/28/2014)... 28, 2014 /PRNewswire/ -   JOLT , a leading ... to join its growing portfolio of startups. Next-level tech ... Toronto,s JOLT accelerator, and Cohort four is ... Since its launch in July 2012, ...  $7.5M of financing. Now at 23 investments, JOLT,s portfolio ...
Breaking Biology Technology:Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2Global Synthetic Biology Market 2014-2018 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 3
... ranking, MADISON, N.J., March 5 Quest Diagnostics,Incorporated ... been selected by,FORTUNE magazine to the 2008 list of ... four companies in the "Health,Care" category of "pharmacy and ... been named to the list., "Our ranking as ...
... NBS ),which is pioneering the pre-disease collection, processing ... need, today announced that,Denis Rodgerson, Ph.D., NeoStem,s Director of ... Las Vegas campus this evening. In,October 2007, NeoStem announced ... centers into Las Vegas, the first in the region., ...
... 5 Barr Pharmaceuticals,Inc. (NYSE: BRL ... Duramed,Pharmaceuticals, Inc., has filed suit against Watson ... Inc., for infringement of the,patent protecting Duramed,s ... Patent No. 7,320,969 is due to expire ...
Cached Biology Technology:Quest Diagnostics Named to FORTUNE Magazine's America's Most Admired Companies List 2NeoStem's Denis Rodgerson, Ph.D. to Lecture on Stem Cells and Regenerative Medicine at University of Nevada Las Vegas Campus 2NeoStem's Denis Rodgerson, Ph.D. to Lecture on Stem Cells and Regenerative Medicine at University of Nevada Las Vegas Campus 3Barr Subsidiary Sues Watson for SEASONIQUE(R) Patent Infringement 2Barr Subsidiary Sues Watson for SEASONIQUE(R) Patent Infringement 3Barr Subsidiary Sues Watson for SEASONIQUE(R) Patent Infringement 4
(Date:7/28/2014)... has identified areas of the Earth that are high ... , Europe is particularly vulnerable, as it has the ... cent, of any continent in ,refugia, areas of ... conditions remain relatively constant during times of great environmental ... mostly in Scandinavia and Scotland. , The biggest ...
(Date:7/28/2014)... the bug hunter, but the target of his work ... identified with special methods and instruments. Benjamin Hause, an ... Laboratory at Kansas State University, recently published an article ... is an important find in the United States. , ... know what it was," Hause said. "We used next-generation ...
(Date:7/28/2014)... Children,s Research Hospital study found that 73 percent of ... risk of developing metabolic syndrome and related health problems ... appear in the current issue of the journal ... adult survivors of childhood cancer in the study had ... like high blood pressure, abdominal obesity, elevated triglyceride and ...
Breaking Biology News(10 mins):Study finds Europe's habitat and wildlife is vulnerable to climate change 2Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 2Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 3
... The Association for Molecular Pathology (AMP) invites members of ... and Exhibits and learn about the latest advances in ... will feature more than 100 corporate exhibits, as well ... keynote speaker is the distinguished recipient of the 2010 ...
... of Washington undergraduate students was among 65 research groups ... Bill & Melinda Gates Foundation,s $100,000 Grand Challenges Explorations ... Grand Challenges Explorations, an initiative to help scientists around ... improve health in developing countries. To receive funding, applicants ...
... 9, 2010 Chimerix, Inc., a ... data supportive of the company,s lead Phase 2 ... late-breaker session by Hans H. Hirsch, MD, MSc, ... University of Basel, Switzerland, at the Antiviral Congress ...
Cached Biology News:Undergraduates' low-cost ultrasound system wins Gates Foundation grant 2Undergraduates' low-cost ultrasound system wins Gates Foundation grant 3Chimerix Antiviral CMX001 Inhibits JC Virus Replication in Preclinical Study; Late-Breaker Presented at Antiviral Congress 2010 2Chimerix Antiviral CMX001 Inhibits JC Virus Replication in Preclinical Study; Late-Breaker Presented at Antiviral Congress 2010 3Chimerix Antiviral CMX001 Inhibits JC Virus Replication in Preclinical Study; Late-Breaker Presented at Antiviral Congress 2010 4Chimerix Antiviral CMX001 Inhibits JC Virus Replication in Preclinical Study; Late-Breaker Presented at Antiviral Congress 2010 5
5(S)-HETE-d8 is used as an internal standard for the quantification of 5(S)-HETE by stable isotope dilution mass spectrometry....
Full-length cDNA clone CS0DJ013YG01 of T cells (Jurkat cell line) of Homo sapiens (human). [Source:Uniprot/SPTREMBL;Acc:Q86SZ3] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
...
...
Biology Products: